-
公开(公告)号：BRPI0915825A2
公开(公告)日：2015-11-03
申请号：BRPI0915825
申请日：2009-07-08
Applicant: ABBOTT LAB
Inventor： MURTAZA ANWAR , HUTCHINS CHARLES W , HSIEH CHUNG-MING , TARCSA EDIT , BELANGER EILEEN , SHEN JIANWEI , GU JIJIE , HARRIS MARIA C , ZHU RONG-RONG , STINE WILLIAM B
IPC: A61K39/395
-
公开(公告)号：ECSP13012648A
公开(公告)日：2013-07-31
申请号：ECSP13012648
申请日：2013-05-30
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , GU JIJIE , LIU JUNJIAN , HARRIS MARÍA C
IPC: A61K39/395 , C07K16/00 , C12P21/08
Abstract: Proteínas de unión multivalentes y multiespecíficas modificadas, métodos para elaborarlas y sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.
-
公开(公告)号：SG188142A1
公开(公告)日：2013-03-28
申请号：SG2013010228
申请日：2009-05-08
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor： GU JIJIE , HSIEH CHUNG-MING , WU ZHEN , DIGIAMMARINO ENRICO L , LUO FENG , FOX GERARD B , HARLAN JOHN E , SCHMIDT MARTIN , LOEBBERT RALF , MUELLER REINHOLD , EBERT ULRICH , NIMMRICH VOLKER
Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid and advanced glycation-end-products.No suitable figure
-
公开(公告)号：NZ590074A
公开(公告)日：2012-12-21
申请号：NZ59007409
申请日：2009-07-08
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , GU JIJIE , ISAKSON PETER C
Abstract: Disclosed is a binding protein comprising a polypeptide chain, wherein said polypeptide chain comprises VDl-(Xl)n-VD2-C-(X2)n, wherein; VDl is a first heavy chain variable domain; VD2 is a second heavy chain variable domain; C is a heavy chain constant domain; Xl is a linker with the proviso that it is not CHl; X2 is an Fc region; and n is 0 or 1; wherein the binding protein is capable of binding a pair of antigens selected from the group consisting of TNF and PGE2, NGF and PGE2, IL- 17A and PGE2, IL-Ib and PGE2, IL-6 and PGE2, IL-6R and PGE2, VEGF and PGE2, Abeta (seq. 1) and PGE2, Abeta (seq. 2) and PGE2, Abeta (seq. 3) and PGE2, IL- 18 and PGE2, PGE2 and PGE2, IL-15 and PGE2, SlP and PGE2, EGFR (seq. 1) and PGE2, EGFR (seq. 2) and PGE2, and IGFR and PGE2.
-
公开(公告)号：MX2012005037A
公开(公告)日：2012-05-22
申请号：MX2012005037
申请日：2010-10-28
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , GU JIJIE , ISAKSON PETER C , HARRIS MARIA C , SALFELD JOCHEN G , MCPHERSON MICHAEL J , LIU JUANJIAN
IPC: A61K39/395 , C07K16/00
Abstract: La presente invención se refiere a proteínas de unión, diseñadas por ingeniería, multivalentes y multiespecíficas, métodos de fabricación, y específicamente a sus usos en la prevención, diagnóstico, y/o tratamiento de enfermedades.
-
Patent Agency Ranking
公开(公告)号：MX2010014573A
公开(公告)日：2011-09-16
申请号：MX2010014573
申请日：2010-12-21
Applicant: ABBOTT LAB
Inventor： HUTCHINS CHARLES W , HSIEH CHUNG-MING , GU JIJIE , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B
IPC: A61K39/395
Abstract: La presente invención abarcar proteínas de unión de prostaglandina E2 (PGE2). La invención se refiere a anticuerpos que son de tipo silvestre, quiméricos, de CDR injertada y humanizados. Los anticuerpos preferidos tienen alta afinidad para prostaglandina E2 y neutralizan la actividad de prostaglandina E2 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa, o una porción de unión a antígeno del mismo. También se proporcionan métodos para hacer y métodos para utilizar los anticuerpos de la invención. Los anticuerpos, o porciones de unión a antígeno, de la invención son útiles para detectar prostaglandina E2 y para inhibir la actividad de prostaglandina E2, por ejemplo, en un ser humano que sufre de un trastorno en donde la actividad de prostaglandina E2 es dañina.
-
公开(公告)号：AU2009268585A1
公开(公告)日：2010-01-14
申请号：AU2009268585
申请日：2009-07-08
Applicant: ABBOTT LAB
Inventor： ISAKSON PETER C , GU JIJIE , GHAYUR TARIQ
IPC: C07K14/705 , A61K38/17
-
公开(公告)号：AU2009245354A1
公开(公告)日：2009-11-12
申请号：AU2009245354
申请日：2009-05-08
Applicant: ABBOTT GMBH & CO KG , ABBOTT LAB
Inventor： GU JIJIE , HSIEH CHUNG-MING , NIMMRICH VOLKER , LOEBBERT RALF , DIGIAMMARINO ENRICO L , EBERT ULRICH , MUELLER REINHOLD , SCHMIDT MARTIN , LUO FENG , FOX GERARD B , HARLAN JOHN E , WU ZHEN
Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid ß and advanced glycation-end-products.
-
公开(公告)号：SG192489A1
公开(公告)日：2013-08-30
申请号：SG2013052725
申请日：2009-07-08
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , GU JIJIE , ISAKSON PETER C
Abstract: PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOFAbstractThe present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Figure 1
-
公开(公告)号：MX2013004979A
公开(公告)日：2013-07-30
申请号：MX2013004979
申请日：2011-11-01
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LIU JUNJIAN , GU JIJIE , HARRIS MARIA C
IPC: C12P21/08 , A61K39/395 , C07K16/00
Abstract: Se proporcionan proteínas de unión multivalentes y multiespecíficas diseñadas por ingeniería, métodos para elaborarlas y sus usos en la prevención, el diagnóstico y/o el tratamiento de enfermedades.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.025 seconds)
